MilliporeSigma
  • Home
  • Search Results
  • Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.

Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.

Journal of the American Society of Hypertension : JASH (2015-09-12)
Joanna E Kontaraki, Maria E Marketou, Fragiskos I Parthenakis, Spyros Maragkoudakis, Evangelos A Zacharis, Stelios Petousis, George E Kochiadakis, Panos E Vardas
ABSTRACT

MicroRNAs regulate several aspects of physiological and pathologic cardiac hypertrophy, and they represent promising therapeutic targets in cardiovascular disease. We assessed the expression levels of the microRNAs miR-1, miR-133a, miR-26b, miR-208b, miR-499, and miR-21, in 102 patients with essential hypertension and 30 healthy individuals. All patients underwent two-dimensional echocardiography. MicroRNA expression levels in peripheral blood mononuclear cells were quantified by real-time reverse transcription polymerase chain reaction. Hypertensive patients showed significantly lower miR-133a (5.06 ± 0.50 vs. 13.20 ± 2.15, P < .001) and miR-26b (6.76 ± 0.53 vs. 9.36 ± 1.40, P = .037) and higher miR-1 (25.99 ± 3.07 vs. 12.28 ± 2.06, P = .019), miR-208b (22.29 ± 2.96 vs. 8.73 ± 1.59, P = .016), miR-499 (10.06 ± 1.05 vs. 5.70 ± 0.91, P = .033), and miR-21 (2.75 ± 0.15 vs. 1.82 ± 0.20, P = .002) expression levels compared with healthy controls. In hypertensive patients, we observed significant negative correlations of miR-1 (r = -0.374, P < .001) and miR-133a (r = -0.431, P < .001) and significant positive correlations of miR-26b (r = 0.302, P = .002), miR-208b (r = 0.426, P < .001), miR-499 (r = 0.433, P < .001) and miR-21 (r = 0.498, P < .001) expression levels with left ventricular mass index. Our data reveal that miR-1, miR-133a, miR-26b, miR-208b, miR-499, and miR-21 show distinct expression profiles in hypertensive patients relative to healthy individuals and they are associated with clinical indices of left ventricular hypertrophy in hypertensive patients. Thus, they may be related to heart hypertrophy in hypertensive patients and are possibly candidate therapeutic targets in hypertensive heart disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, puriss. p.a., crystallized, ≥99.0% (T)
Sigma-Aldrich
Creatinine, anhydrous, ≥98%
Sigma-Aldrich
Uric acid, ≥99%, crystalline
Sigma-Aldrich
Pyrvinium pamoate salt hydrate, ≥98% (HPLC)
Sigma-Aldrich
Sodium phosphate dibasic dodecahydrate, BioXtra, ≥99.0% (T)
SAFC
Cholesterol, Plant-Derived, SyntheChol®, NF, Ph. Eur., JP
Sigma-Aldrich
DBP, 98% (HPLC)
Sigma-Aldrich
Uric acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
Dibutyl phthalate, 99%
Sigma-Aldrich
Cholesterol, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
Cholesterol, Sigma Grade, ≥99%
Sigma-Aldrich
Cholesterol, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, sterile-filtered, aqueous solution, suitable for cell culture
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
SAFC
Cholesterol, from sheep wool, Controlled origin, meets USP/NF testing specifications